VCM
FPRX

Versant Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Versant Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50
Closed – – 1689
2019
Q3 		$0 Buy
+50
New +$274 ﹤0.01% 1691

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Versant Capital Management's FPRX Position: Q4 2019 in Review

Versant Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2019, closing a stake of 50 shares.

Versant Capital Management first reported a position in FPRX in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 94 funds tracked by Wall St. Rank hold FPRX as of Q4 2019.

  • Versant Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Versant Capital Management sold 50 Five Prime Therapeutics, Inc. shares in Q4 2019.
  • Versant Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2019 and held it in 1 quarter.
  • Versant Capital Management's Five Prime Therapeutics, Inc. position peaked at $0 in Q3 2019.
  • 94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2019.

Based on Versant Capital Management's 13F filing for Q4 2019, filed 28 Jan 2020.